Tayal Vandana, Mandal Akash, Haque M Ijasul, Mishra Akhilesh, Kalra Bhupinder S, Roy Vandana
Department of Pharmacology, Maulana Azad Medical College, New Delhi 110002, India.
Department of Pharmacology, MES Medical College, Perintalmanna 679338, Kerala, India.
World J Methodol. 2025 Jun 20;15(2):99580. doi: 10.5662/wjm.v15.i2.99580.
Epilepsy impacts millions of people, with many not responding to existing treatments. Some evidence links neuroinflammatory processes to epilepsy. Statins exhibit anti-inflammatory and neuroprotective properties, potentially offering antiepileptic effects.
To evaluate the anticonvulsant effects of rosuvastatin in animal models of epilepsy.
Ninety-six albino mice were divided into 16 groups. In the maximal electroshock seizure (MES) model, eight groups received intraperitoneal vehicle, carbamazepine, rosuvastatin, or a combination. Outcomes measured included seizure protection [tonic hind limb extension (THLE)], duration of THLE, seizure duration, and mortality. In the pentylenetetrazol (PTZ) model, eight groups were pretreated with vehicle, valproate, rosuvastatin, or a combination, with outcomes measured as seizure latency, seizure duration, and mortality.
In the MES model, rosuvastatin exhibited protection against THLE in a small percentage of mice. Rosuvastatin shortens the duration of THLE in a dose-dependent manner. However, none of these were statistically significant compared to the control group. The combination of rosuvastatin 10 mg/kg with carbamazepine 4 mg/kg resulted in a significant reduction in seizure duration compared to the control group, better than carbamazepine alone at 4 mg/kg and 6 mg/kg. In the PTZ model, rosuvastatin alone showed no significant effects on latency, duration of seizure, or mortality. However, rosuvastatin 10 mg/kg combined with valproate 100 mg/kg significantly delayed the onset of seizures, seizure duration and mortality percentage, better than valproate alone at 100 mg/kg.
Rosuvastatin enhanced the anticonvulsant effects of carbamazepine and valproate. Further studies are required to explore the antiepileptic potential of rosuvastatin at various doses, durations, dosage forms, routes and models.
癫痫影响着数百万人，许多人对现有治疗方法没有反应。一些证据将神经炎症过程与癫痫联系起来。他汀类药物具有抗炎和神经保护特性，可能具有抗癫痫作用。
评估瑞舒伐他汀在癫痫动物模型中的抗惊厥作用。
将96只白化小鼠分为16组。在最大电休克惊厥（MES）模型中，8组分别腹腔注射赋形剂、卡马西平、瑞舒伐他汀或联合用药。测量的结果包括惊厥保护[强直性后肢伸展（THLE）]、THLE持续时间、惊厥持续时间和死亡率。在戊四氮（PTZ）模型中，8组分别用赋形剂、丙戊酸盐、瑞舒伐他汀或联合用药进行预处理，测量的结果为惊厥潜伏期、惊厥持续时间和死亡率。
在MES模型中，瑞舒伐他汀在一小部分小鼠中表现出对THLE的保护作用。瑞舒伐他汀以剂量依赖的方式缩短THLE的持续时间。然而，与对照组相比，这些均无统计学意义。与对照组相比，10mg/kg瑞舒伐他汀与4mg/kg卡马西平联合使用可显著缩短惊厥持续时间，优于单独使用4mg/kg和6mg/kg的卡马西平。在PTZ模型中，单独使用瑞舒伐他汀对潜伏期、惊厥持续时间或死亡率均无显著影响。然而，10mg/kg瑞舒伐他汀与100mg/kg丙戊酸盐联合使用可显著延迟惊厥发作、惊厥持续时间和死亡率百分比，优于单独使用100mg/kg的丙戊酸盐。
瑞舒伐他汀增强了卡马西平和丙戊酸盐的抗惊厥作用。需要进一步研究探索瑞舒伐他汀在不同剂量、持续时间、剂型、给药途径和模型中的抗癫痫潜力。
